BACKGROUND AND PURPOSE: Inflammation is considered to be involved in the pathogenesis of ischemic stroke. Our purpose was to assess the role of soluble intercellular adhesion molecule-1 (sICAM-1) concentration, a marker of inflammation, in predicting future ischemic stroke among patients at risk because of chronic coronary heart disease. METHODS: We obtained baseline serum samples from patients with chronic coronary heart disease enrolled in the Bezafibrate Infarction Prevention trial (n=3090), which assessed the efficacy of bezafibrate in secondary prevention. Using a prospective nested case-control design, we measured baseline sICAM-1 concentration in sera of patients who developed ischemic stroke during a mean follow-up of 8.2 years (cases, n=134) and in age- and sex-matched controls without any subsequent cardiovascular events (n=134). RESULTS: Baseline serum concentrations of sICAM-1 were significantly higher in cases compared with controls (379 versus 350 ng/mL, P<0.05). sICAM-1 concentration at the highest quartile (>394 ng/mL) was associated with significantly higher relative odds of ischemic stroke compared with the lower concentrations after adjustment for potential confounding variables (relative odds, 2.1; 95% CI, 1.1 to 4.3). After fibrinogen and total white blood cell count were added to the multivariable model, the relative odds were 2.1 (95% CI, 1.1 to 4.2) and 2.2 (95% CI, 1.1 to 4.8), respectively. The risk associated with raised concentrations of sICAM-1 seemed to be highest for large disabling strokes of cardioembolic origin. CONCLUSIONS: Elevated concentrations of sICAM-1, a marker of inflammation, are associated with increased risk of ischemic stroke, independent of other traditional cerebrovascular risk factors and of plasma fibrinogen, among patients at increased risk because of manifest coronary heart disease.
BACKGROUND AND PURPOSE:Inflammation is considered to be involved in the pathogenesis of ischemic stroke. Our purpose was to assess the role of soluble intercellular adhesion molecule-1 (sICAM-1) concentration, a marker of inflammation, in predicting future ischemic stroke among patients at risk because of chronic coronary heart disease. METHODS: We obtained baseline serum samples from patients with chronic coronary heart disease enrolled in the BezafibrateInfarction Prevention trial (n=3090), which assessed the efficacy of bezafibrate in secondary prevention. Using a prospective nested case-control design, we measured baseline sICAM-1 concentration in sera of patients who developed ischemic stroke during a mean follow-up of 8.2 years (cases, n=134) and in age- and sex-matched controls without any subsequent cardiovascular events (n=134). RESULTS: Baseline serum concentrations of sICAM-1 were significantly higher in cases compared with controls (379 versus 350 ng/mL, P<0.05). sICAM-1 concentration at the highest quartile (>394 ng/mL) was associated with significantly higher relative odds of ischemic stroke compared with the lower concentrations after adjustment for potential confounding variables (relative odds, 2.1; 95% CI, 1.1 to 4.3). After fibrinogen and total white blood cell count were added to the multivariable model, the relative odds were 2.1 (95% CI, 1.1 to 4.2) and 2.2 (95% CI, 1.1 to 4.8), respectively. The risk associated with raised concentrations of sICAM-1 seemed to be highest for large disabling strokes of cardioembolic origin. CONCLUSIONS: Elevated concentrations of sICAM-1, a marker of inflammation, are associated with increased risk of ischemic stroke, independent of other traditional cerebrovascular risk factors and of plasma fibrinogen, among patients at increased risk because of manifest coronary heart disease.
Authors: Monik C Jiménez; Kathryn M Rexrode; Gregory Kotler; Brendan M Everett; Robert J Glynn; I-Min Lee; Julie E Buring; Paul M Ridker; Howard D Sesso Journal: Am J Hypertens Date: 2016-05-28 Impact factor: 2.689
Authors: Robert C Kaplan; Aileen P McGinn; Alison E Baird; Susan L Hendrix; Charles Kooperberg; John Lynch; Daniel M Rosenbaum; Karen C Johnson; Howard D Strickler; Sylvia Wassertheil-Smoller Journal: J Stroke Cerebrovasc Dis Date: 2008 Nov-Dec Impact factor: 2.136
Authors: Xiao Xia Li; Jian Ping Liu; Jin Quan Cheng; Sheng Hong Han; Yi Jie Geng; Sheng Wei; Shi Tong Gao; Da Na Huang; Shao Fa Nie Journal: Mol Biol Rep Date: 2008-09-14 Impact factor: 2.316
Authors: N Sattar; H M Murray; P Welsh; G J Blauw; B M Buckley; A J de Craen; I Ford; N G Forouhi; D J Freeman; J W Jukema; P W Macfarlane; M B Murphy; C J Packard; D J Stott; R G J Westendorp; J Shepherd Journal: Diabetologia Date: 2008-11-22 Impact factor: 10.122
Authors: Jagdish Gondalia; Björn Fagerberg; Johannes Hulthe; Lars Karlström; Ulf Nilsson; Susanna Waters; Olof Jonsson Journal: Int J Med Sci Date: 2007-04-14 Impact factor: 3.738